UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 26, 2006
GENTA INCORPORATED
(Exact Name of Registrant as Specified in Charter)
|
Delaware |
000-19635 |
33-0326866 |
|
(State or Other Jurisdiction |
(Commission File Number) |
(I.R.S. Employer |
|
Two Connell Drive, Berkeley Heights, NJ |
07922 |
|
(Address of Principal Executive Offices) |
(Zip Code) |
(908) 286-9800
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 26, 2006, Genta Incorporated, a Delaware corporation (the “Company”), issued a press release announcing that the Company’s proposal for a confirmatory trial of Genasense® (oblimersen sodium) Injection in patients with chronic lymphocytic leukemia (CLL) has completed Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA).
A copy of the press release is filed as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
|
99.1 |
Press Release of the Company dated July 26, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GENTA INCORPORATED |
|||
|
By: |
/s/ Richard J. Moran |
||
|
Dated: July 26, 2006 |
Richard J. Moran
Senior Vice President, Chief Financial |
||